Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.

In the initial publication, only a weak trend was observed between the antitumor activity of loncastuximab tesirine and CD19 expression levels across ten cell lines, including CD19-negative cells. 11 Here, we expanded the number of cell lines analyzed and, even when focusing only on B-cell lymphoma models, we observed a significant correlation

also in 1,404 other papers